Dornase alfa, sold under the brand name Pulmozyme, is used for the treatment of cystic fibrosis.[3] It is a recombinant human deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA.[3] Dornase alfa hydrolyzes the DNA present in sputum/mucus and reduces viscosity in the lungs, promoting improved clearance of secretions.[3] It is produced in Chinese hamster ovary cells.[3]
Clinical data | |
---|---|
Trade names | Pulmozyme |
AHFS/Drugs.com | Monograph |
MedlinePlus | a694002 |
License data |
|
Pregnancy category |
|
Routes of administration | Inhalation |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
CAS Number |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
CompTox Dashboard (EPA) |
|
ECHA InfoCard | 100.029.685 |
Chemical and physical data | |
Formula | C1321H1999N339O396S9 |
Molar mass | 29254.04 g·mol−1 |
(what is this?) (verify) |
Dornase alfa is indicated for the management of people with cystic fibrosis to improve pulmonary function.[3]
Dornase alfa is an orphan drug.[4]
Dornase alfa has been shown to improve lung function in non-cystic fibrosis pre-term infants atelectasis.[5][6]